Fidelity Investments
FBRX icon

Fidelity Investments’s Forte Biosciences FBRX Stock Holding History

Fidelity Investments’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.82M Buy
340,695
+29,730
+10% +$856K ﹤0.01% 2089
2025
Q4 		$8.48M Buy
310,965
+66,565
+27% +$1.17M ﹤0.01% 2089
2025
Q3 		$3.67M Buy
+244,400
New +$2.81M ﹤0.01% 2337
2024
Q3 		– Sell
-5
Closed -$69 – 5563
2024
Q2 		$69 Buy
+5
New +$81 ﹤0.01% 5008
2022
Q3 		– Sell
-24
Closed -$1K – 5024
2022
Q2 		$1K Buy
24
+11
+85% +$349 ﹤0.01% 4707
2022
Q1 		$0 Buy
+13
New +$492 ﹤0.01% 5126
2018
Q4 		– Sell
-941
Closed -$5.5M – 3679
2018
Q3 		$5.5M Sell
941
-424
-31% -$1.61M ﹤0.01% 2125
2018
Q2 		$4.78M Sell
1,365
-735
-35% -$2.69M ﹤0.01% 2164
2018
Q1 		$9.33M Sell
2,100
-19
-0.9% -$88K ﹤0.01% 1979
2017
Q4 		$8.15M Buy
2,119
+53
+3% +$212K ﹤0.01% 2011
2017
Q3 		$9.65M Sell
2,066
-67
-3% -$298K ﹤0.01% 1948
2017
Q2 		$9.62M Buy
+2,133
New +$12M ﹤0.01% 1958

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Fidelity Investments's FBRX Position: Q1 2026 in Review

Fidelity Investments increased its Forte Biosciences (FBRX) stake by 9.6% in Q1 2026, buying an estimated $856K and bringing the position to 340,695 shares worth $8.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2089.

Fidelity Investments first reported a position in FBRX in Q2 2017 and has held it in 12 quarters since. The position peaked at $9.65M in Q3 2017. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Fidelity Investments held 340,695 shares of Forte Biosciences worth $8.82M as of Q1 2026.
  • Fidelity Investments bought 29,730 Forte Biosciences shares in Q1 2026, an estimated $856K.
  • Forte Biosciences made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2089 holding.
  • Fidelity Investments first reported a position in Forte Biosciences in Q2 2017 and has held it in 12 quarters since.
  • Fidelity Investments's Forte Biosciences position peaked at $9.65M in Q3 2017.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.